The norepinephrine level is decreased in the lymphocytes of long-term interferon-beta-treated multiple sclerosis patients

Abstract

The mutual involvement of dopamine and its metabolites in the nervous and immune systems has the potential to provide information on the interaction of these two systems. During a 24-hour period, we used capillary electrophoresis with electrochemical detection to repeatedly measure the intracellular catecholamine concentrations in the peripheral blood lymphocytes of relapsing-remitting multiple sclerosis (RRMS) patients receiving interferon (IFN)-beta-1b (n = 13), and those of IFN-naïve RRMS patients receiving their first IFN-beta-1a injection (n = 19) during this study, and compared them with the levels in healthy controls (n = 12). At baseline, the norepinephrine level was significantly decreased (P = 0.003) in the long-term IFN MS patients compared with the controls. The Time × Group interactions for dopamine (P= 0.5854) and norepinephrine (P = 0.6192) were not significant. The group effects for the individual drugs were P = 0.3529 and 0.1282, respectively. The lower norepinephrine level at baseline in the long-term IFN MS group suggests an immunologically stable phase, in line with our previous findings. This is the first report of the effects of IFN-beta administration on intracellular catecholamines in MS patients. Further studies are necessary to elucidate the immune reactions affected by the catecholamines in MS and to evaluate the roles of these potential immunotransmitters.

Keywords

capillary electrophoresis catecholamine dopamine human peripheral blood lymphocyte interferon-beta multiple sclerosis norepinephrine relapsing-remitting

Get full access to this article

View all access options for this article.

References

Besedovsky HO , del Rey A. Immune-neuro-endocrine interactions: facts and hypotheses . Endocr Rev 1996; 17: 64-102 .

Schedlowski M , Hosch W , Oberbeck R , Benschop RJ , Jacobs R , Raab HR et al. Catecholamines modulate human NK cell circulation and function via spleen-independent beta 2-adrenergic mechanisms . J Immunol 1996; 156: 93-99 .

Turnbull AV , Rivier CL. Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action . Physiol Rev 1999; 79: 1-71 .

Pacheco-Lopez G , Niemi MB , Kou W , Bildhauser A , Gross CM , Goebel MU et al. Central catecholamine depletion inhibits peripheral lymphocyte responsiveness in spleen and blood . J Neurochem 2003; 86: 1024-1031 .

Rajda C , Bencsik K , Vécsei L , Bergquist J. Catecholamine levels in peripheral blood lymphocytes from multiple sclerosis patients . J Neuroimmunol 2002; 124: 93-100 .

Noseworthy JH , Lucchinetti C , Rodriguez M , Weinshenker BG. Multiple sclerosis . N Engl J Med 2000; 343: 938-952 .

Milo R , Panitch H. Glatiramer acetate or interferon-beta for multiple sclerosis? A guide to drug choice . CNS Drugs 1999; 11: 289-306 .

Elenkov IJ , Wilder RL , Chrousos GP , Vizi ES. The sympathetic nerve-an integrative interface between two supersystems: the brain and the immune system . Pharmacol Rev 2000; 52: 595-638 .

Sanders VM , Straub RH. Norepinephrine, the beta-adrenergic receptor, and immunity . Brain Behav Immun 2002; 16: 290-332 .

10.

Zoukos Y , Leonard JP , Thomaides T , Thompson AJ , Cuzner ML. Beta-adrenergic receptor density and function of peripheral blood mononuclear cells are increased in multiple sclerosis: a regulatory role for cortisol and interleukin-1 . Ann Neurol 1992; 31: 657-662 .

11.

Karaszewski JW , Reder AT , Anlar B , Kim WC , Arnason BGW. Increased lymphocyte beta-adrenergic receptor density in progressive multiple sclerosis is specific for the CD8+, CD28- suppressor cell . Ann Neurol 1991; 30: 42-47 .

12.

Zoukos Y , Thomaides TN , Kidd D , Cuzner ML , Thompson A. Expression of beta2 adrenoreceptors on peripheral blood mononuclear cells in patients with primary and secondary progressive multiple sclerosis: a longitudinal six month study . J Neurol Neurosurg Psychiatry 2003; 74: 197-202 .

13.

Rott O , Cash E , Fleischer B. Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1- but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats . Eur J Immunol 1993; 23: 1745-1751 .

14.

Wiegmann K , Muthyala S , Kim DH , Arnason BGW , Chelmika-Schorr E. Beta-adrenergic agonist suppress chronic/relapsing experimental allergic encephalomyelitis (CREAE) in Lewis rats . J Neuroimmunol 1995; 56: 201-206 .

15.

De Keyser J , Wiczak N , Leta R , Streetland C. Astrocytes in multiple sclerosis lack beta-2 adrenergic receptors . Neurology 1999; 53: 1628-1633 .

16.

Zeinstra E , Wilczak N , Streefland C , De Keyser J. Astrocytes in chronic active multiple sclerosis plaques express MHC class II molecules . Neuroreport 2000; 11: 89-91 .

17.

Bergquist J , Tarkowski A , Ewing A , Ekman R. Catecholaminergic suppression of immunocompetent cells . Immunol Today 1998; 19: 562-567 .

18.

Cosentino M , Marino F , Bombelli R , Ferrari M , Lecchini S , Frigo G. Endogenous catecholamine synthesis, metabolism, storage and uptake in human neutrophils . Life Sci 1999; 64: 975-981 .

19.

Musso NR , Brenci S , Indiveri F , Lotti G. Acetylcho-line-induced, calcium-dependent norepinephrine outflow from peripheral human lymphocytes . J Neuroimmunol 1998; 87: 82-87 .

20.

Mann MB , Wu S , Rostamkhani M , Tourtellotte W , MacMurray JP , Comings DE. Association between the phenylethanolamine N -methyltransferase gene and multiple sclerosis . J Neuroimmunol 2002; 124: 101-105 .

21.

Flachenecker P , Jung S , Rieckmann P , Toyka KV. sICAM-1 is not a marker for disease activity in the relapse-free interval of multiple sclerosis-a cross-sectional pilot study . J Neurol 2002; 249: 1001-1003 .

22.

Heesen C , Schulz H , Schmidt M , Gold S , Tessmer W , Schulz KH. Endocrine and cytokine responses to acute psychological stress in multiple sclerosis . Brain Behav Immunol 2002; 16: 282-287 .

23.

Barkhatova VP , Zavalishin IA , Askarova LSH , Shavratskii VKH , Demina EG. Changes in neuro-transmitters in multiple sclerosis . Neurosci Behav Physiol 1998; 28: 341-344 .

24.

Cosentino M , Zaffaroni M , Marino F , Bombelli R , Ferrari M , Rasini E et al. Catecholamine production and tyrosine hydroxylase expression in peripheral blood mononuclear cells from multiple sclerosis patients: effect of cell stimulation and possible relevance for activation-induced apoptosis . J Neuroimmunol 2002; 133: 233-240 .

25.

Haerter K , Vroon A , Kavelaars A , Heijnen CJ , Limmroth V , Espinosa E et al. In vitro adrenergic modulation of cellular immune functions in experimental autoimmune encephalomyelitis . J Neuroimmunol 2004; 146: 126-132 .

26.

Heesen C , Gold SM , Sondermann J , Tessmer W , Schulz KH. Oral terbutaline differentially affects cytokine (IL-10, IL-12, TNF-IFNg) release in multiple sclerosis and controls . J Neuroimmunol 2002; 132: 189-195 .

27.

Heesen C , Gold SM , Hartmann S , Mladek M , Reer R , Braumann KM et al. Endocrine and cytokine responses to standardized physical stress in multiple sclerosis . Brain Behav Immun 2003; 17: 473-481 .

28.

Lachenecker P , Reiners K , Krauser M , Wolf A , Toyka KV. Autonomic dysfunction in multiple sclerosis is related to disease activity and progression of disability . Mult Scler 2001; 7: 327-334 .

29.

de Vera N , Cristofol RM , Rodriguez-Farre E. Protein binding and stability of norepinephrine in human blood plasma. Involvement of prealbumin, alpha 1-acid glyco-protein and albumin . Life Sci 1988; 43: 1277-1286 .

30.

Poser CM , Paty DW , Scheinberg L , McDonald WI , Davis FA , Ebers GC. New diagnostic criteria for multiple sclerosis: guidelines for research protocols . Ann Neurol 1983; 13: 227-231 .

31.

Bergquist J , Tarkowski A , Ekman R , Ewing A. Discovery of endogenous catecholamines in lymphocytes and evidence for catecholamine regulation of lymphocyte function via an autocrine loop . Proc Natl Acad Sci USA 1994; 91: 12912-12916 .

32.

Goebel MU , Baase J , Pithan V , Exton M , Saller B , Schedlowski M et al. Acute interferon beta-1b administration alters hypothalamic-pituitary-adrenal axis activity, plasma cytokines and leukocyte distribution in healthy subjects . Psychoneuroendocrinology 2002; 27: 881-892 .

33.

Durelli L. Dose and frequency of interferon treatment matter-INCOMIN and OPTIMS . J Neurol 2003; 250: 9-14 .

34.

Sturzebecher S , Maibauer R , Heuner A , Beckmann K , Aufdembrinke B. Pharmacodynamic comparison of single doses of IFN-beta1a and IFN-beta1b in healthy volunteers . J Interferon Cytokine Res 1999; 19: 1257-1264 .